Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
Shuo Yang 1, Yan Wang 1, Chao Zhao 2, Xuefei Li 2, Qian Liu 1, Shiqi Mao 1, Yiwei Liu 1, Xiaofei Yu 1, Wanying Wang 1, Qinrun Tian 1, Yingying Pan 1, Anwen Xiong 1, Bin Chen 1, Guanghui Gao 1, Wei Li 1, Yayi He 1, Fengying Wu 1, Xiaoxia Chen 1, Chunxia Su

YVMA insertion is associated with a higher incidence of brain metastasis, and inferior outcomes to chemotherapy

than non-YVMA variants in patients with advanced NSCLC and HER2 kinase domain mutations, which emphasized

the unmet need of more potent anti-cancer therapies with high blood-brain barrier (BBB) penetration capacity for

patients with YVMA insertion.

Transl Lung Cancer Res. 2021 Feb;10(2):753-765. 

Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC
Xuejing Chen Kun Li Zichen Liu Fei Gai Guanshan Zhu Shun Lu Nanying Che

 CfDNA and cfRNA derived from pleural effusion supernatant have been successfully tested with a PCR-based

multigene detection kit. Pleural effusion supernatant seems a preferred material for detection of multigene

alterations to guide treatment decision of advanced NSCLC.

Cancer Med. 2021 Apr;10(7):2286-2292.

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
Liang Shi1, Junfang Tang1, Hong Tao1, Lili Guo1, Weihua Wu1, Hongbo Wu1, Zichen Liu2, Li Tong1, Wei Wu1, Hongxia Li1, Qiyi Meng1, Liyan Xu1, Nanying Che2 and Zhe Liu

 It was feasible to test EGFR mutation in cerebrospinal fluid and plasma. In LADC patients with brain metastasis,

cerebrospinal fluid can be used as a liquid biopsy specimen to guide treatment strategy by monitoring EGFR

mutation status.

Front. Oncol., 22 March 2021

Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing
Shuji Murakami,1,* Tomoyuki Yokose,2 Daiji Nemoto,3 Masaki Suzuki,2 Ryou Usui,1 Yoshiro Nakahara,1 Tetsuro Kondo,1 Terufumi Kato,1 and Haruhiro Saito

 Regardless of the device used, a tissue surface area of ≥ 1 mm2 is adequate for samples to be tested with NGS.

Diagnostics (Basel). 2021 Feb 25;11(3):391. 

Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China
Yongchun Zhou1†, Feng Ge2†, Yaxi Du1, Quan Li1, Jingjing Cai1, Xin Liu1, Yinjin Guo1, Zhenghai Shen3, Lincan Duan4, Zhan Huang5, Fei Yao5, Changbin Zhu5, Hutao Shi6* and Yunchao Huang

Patients with NSCLC in Qujing displayed a unique profile of driver gene mutations, especially a higher prevalence of

EGFR compound mutations and dominant KRAS G12C subtype, in this study, indicating a peculiar etiology of NSCLC

in Qujing. Therefore, a different paradigm of therapeutic strategy might need to be considered for patients with

NSCLC in Qujing.

Front. Oncol., 13 April 2021

CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer
Shi Chen # 1 2, Can Yang # 3, Zu-Wei Wang # 3, Jian-Fei Hu # 3, Jing-Jing Pan 3, Cheng-Yu Liao 3, Jia-Qiang Zhang 4, Jiang-Zhi Chen 5, Yi Huang 3 6, Long Huang 3 7, Qian Zhan 4, Yi-Feng Tian 3 7, Bai-Yong Shen 8, Yao-Dong Wang

The CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2, which promotes growth and

metastasis and regulates m6A methylation of PDAC cells. This study suggests the potential prognostic value and

therapeutic targeting of this pathway in PDAC patients.

J Hematol Oncol. 2021 Apr 13;14(1):60.